Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

VB10.16 Plus Atezolizumab Generates Positive Survival Data in PD-L1+ Advanced Cervical Cancer

April 20th 2023

The combination of the potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate VB10.16 and atezolizumab elicited a median overall survival greater than 25 months in patients with PD-L1–positive, human papillomavirus 16–positive advanced cervical cancer.

HECTOR Deep Learning Model Shows Predictability for Distant Recurrence Risk in Endometrial Cancer

April 18th 2023

A deep learning risk prediction model was able to accurately identify patients with endometrial cancer at low and high risk of distant recurrence, according to data presented during the 2023 AACR Annual Meeting.

Awareness of the HPV-Cancer Connection, Vaccine Rates Are Lagging

April 18th 2023

Fewer Americans are aware of the fact that the human papillomavirus can cause certain types of cancer, and vaccination rates against the virus are lagging, according to recent research presented at the AACR Annual Meeting 2023.

Dostarlimab in Combination with Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer: A Placebo-Controlled Randomized Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

April 18th 2023

Mansoor R. Mirza, MD, reviews data from the phase 3 RUBY trial investigating dostarlimab in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer.

Trastuzumab Deruxtecan Displays Antitumor Activity, Safety in HER2-Expressing Uterine Carcinosarcoma

April 14th 2023

The antibody-drug conjugate trastuzumab deruxtecan led to durable responses and a tolerable safety profile in patients with HER2-expressing uterine carcinosarcoma.

Early Success With Olaparib Plus Selumetinib Leads to Further Exploration in RAS-mutated Gynecologic Cancers

April 14th 2023

Shannon N. Westin, MD, MPH, FACOG, shares preclinical data that provided the impetus for the SOLAR trial of olaparib and selumetinib in patients with RAS-mutated gynecologic cancers, key findings from the dose-escalation and -expansion portions of the research, and next steps with the combination.

Dr Fader on Letrozole With or Without Paclitaxel and Carboplatin in Ovarian Serous Carcinoma

April 13th 2023

Amanda Nickles Fader, MD, discusses the randomized, phase 3 NRG-GY019 trial evaluating letrozole with or without paclitaxel and carboplatin in patients with stage II to IV primary low-grade serous carcinoma of the ovary or peritoneum.

Dr Slomovitz on the Classification of Molecular Subtypes to Guide Treatment in Endometrial Cancer

April 13th 2023

Brian M. Slomovitz, MD, discusses the classification of molecular subtypes to guide treatment and care in endometrial cancers.

Dr Cun on Molecular Classification in Endometrioid Endometrial Adenocarcinoma

April 13th 2023

Han T. Cun, MD, MS, discusses the findings from a retrospective comprehensive molecular classification of patients with grade 3 endometrioid endometrial adenocarcinoma.

FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer

April 13th 2023

Dr Gilbert discusses the FDA approval of dostarlimab in patients with endometrial cancer, key efficacy data from the GARNET trial, and how this agent bolsters the endometrial cancer treatment paradigm.

Individualized Treatment Strategies Strengthen Gynecologic Oncology Armamentarium

April 12th 2023

Marilyn Huang, MD, contextualizes findings within the endometrial cancer treatment landscape and emphasizes the unanswered questions regarding optimal therapies for patients with mismatch repair–proficient disease.

Dr Fashemi on the Effect of Entinostat on Olaparib Responsiveness in Mouse HRP Ovarian Cancer Models

April 12th 2023

Bisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.

Dr John on the Antitumor Effects of Sulindac in an Obesity-Driven Model of Endometrial Cancer

April 12th 2023

Catherine John, MD, discusses the antitumor effects of sulindac on the prevention and treatment of obesity-driven models of endometrial cancer.

Eskander Highlights PFS Outcomes With Pembrolizumab in dMMR/pMMR Advanced Endometrial Cancer

April 12th 2023

Ramez N. Eskander, MD, highlights the potential implications of the NRG GY018 trial as well as safety and efficacy results from the trial.

Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates

April 10th 2023

Presenters from the 2023 SGO Annual Meeting share their insights on the treatment of patients with gynecologic cancers.

NGS Reveals Molecular Subgroups in Endometrioid Ovarian Carcinoma

April 9th 2023

The use of next-generation sequencing demonstrated that the most prevalent genomic alterations in patients with endometrioid ovarian carcinoma include ARID1A, PIK3CA, PTEN, CTNNB1, KRAS, and P53.

Dostarlimab Plus Chemotherapy Shows Survival Benefit, Fills Unmet Need for Patients With Recurrent Endometrial Cancer

April 6th 2023

Combining the immune checkpoint inhibitor dostarlimab-gxly with standard-of-care chemotherapy elicited an increase in progression-free survival rates compared with chemotherapy alone for patients with primary advanced or recurrent endometrial cancer.

Dr Zeybek on the Investigation of Neoadjuvant Olaparib in Newly Diagnosed BRCA-Mutant Ovarian Cancer

April 5th 2023

Burak Zeybek, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.

Not All Stage I and II Endometrial Cancers Are Alike

April 5th 2023

A recent retrospective study found that patients with endometrial cancer in International FICO stage I high- intermediate risk subgroups with fewer than 2 risk factors had a greater than 95% cause-specific survival at 3-year follow-up, and subgroups with 2 or more risk factors had poorer outcomes.

Dr Barber on the Significance of the KEYNOTE-775 Trial for the Second-line Treatment of Endometrial Cancer

April 4th 2023

Emma L. Barber, MD, discusses how key data from the phase 3 KEYNOTE-775 study improved the identification of patient populations within endometrial cancer that benefit from second-line immunotherapy.